Quarterly report [Sections 13 or 15(d)]

Stock-based Compensation - Additional Information (Details)

v3.25.2
Stock-based Compensation - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Feb. 28, 2025
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Mar. 31, 2025
Jan. 03, 2025
Jun. 07, 2024
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]                
Common stock shares reserved for issuance           7,448,531    
Stock-based compensation expense   $ 4,208,742 $ 30,697 $ 6,250,938 $ 84,131      
Employee Stock Option                
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]                
Number of stock options granted       25,756,010 188,039      
Stock option, strike price   $ 2.42 $ 2.12 $ 2.42 $ 2.12      
Stock option, aggregate grant date fair value   $ 53,200,000 $ 359,032 $ 53,200,000 $ 359,032      
Performance-based options, Granted       2,056,049 45,000      
Performance-based options, weighted average strike price       $ 2.35 $ 2.16      
Restricted Stock [Member] | CorHepta Pharmaceuticals [Member]                
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]                
Stock-based compensation expense   700,000   $ 1,000,000        
Restricted share issued 1,660,222              
Service based vesting shares 996,133              
Performance based vesting shares 166,023              
Service and performance based vesting shares 498,066              
Fair Value Of Restricted Stock Granted       4,900,000        
Unreognized Compensation Cost   $ 3,900,000   $ 3,900,000        
Two Thousand And Twenty Plan [Member]                
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]                
Plan modification       On June 27, 2025, the stockholders approved an amendment to the 2020 Plan, pursuant to which an automatic evergreen provision was added to provide for an annual increase in January to the number of shares available for issuance under the 2020 Plan and to extend the term of such plan by approximately five years to 2030.        
Number of shares available for grant             31,424,909  
Common stock shares reserved for issuance             27,453,993 2,500,000